AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-11-11
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose
expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity,
pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.